These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 30456712)

  • 21. Gaucher disease.
    Mignot C; Gelot A; De Villemeur TB
    Handb Clin Neurol; 2013; 113():1709-15. PubMed ID: 23622393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
    Dandana A; Ben Khelifa S; Chahed H; Miled A; Ferchichi S
    Pathobiology; 2016; 83(1):13-23. PubMed ID: 26588331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease.
    Jackson KL; Viel C; Clarke J; Bu J; Chan M; Wang B; Shihabuddin LS; Sardi SP
    Neurobiol Dis; 2019 Oct; 130():104513. PubMed ID: 31233883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Gaucher disease: enzyme replacement therapy.
    Zimran A; Elstein D
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():82-7. PubMed ID: 25345089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gaucher disease: clinical, genetic and therapeutic aspects].
    Germain DP
    Pathol Biol (Paris); 2004 Jul; 52(6):343-50. PubMed ID: 15261378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characterization of type 3 (neuronopathic) Gaucher disease in Thai patients.
    Suwannarat P; Keeratichamroen S; Wattanasirichaigoon D; Ngiwsara L; Cairns JR; Svasti J; Visudtibhan A; Pangkanon S
    Blood Cells Mol Dis; 2007; 39(3):348-52. PubMed ID: 17689991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matched unrelated bone marrow transplantation without splenectomy for a child with Gaucher disease caused by homozygosity of the L444P mutation, who also suffered from schizencephaly.
    Chen RL; Hou JW; Chang PY; Tsai FJ; Wang PJ
    J Pediatr Hematol Oncol; 2007 Jan; 29(1):57-9. PubMed ID: 17230068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
    Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
    Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A; Mewawalla P; Jagadeesh S; Kabra M; Phadke SR; Verma IC; Puri RD; Gupta N; Kishnani PS; Mistry PK
    Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic targets in Gaucher's disease].
    Giraldo P; Roca M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():46-9. PubMed ID: 22230126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
    Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A
    Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC; Chien YH; Lai MY; Hwu WL
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
    Krug BC; Schwartz IV; Lopes de Oliveira F; Alegra T; Campos Martins NL; Todeschini LA; Picon PD
    Public Health Genomics; 2010; 13(1):27-33. PubMed ID: 19407439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Successful treatment with enzyme replacement therapy for pelvic fragile fracture in an elderly case of type I Gaucher's disease].
    Matsubara C; Yamamoto K; Maeda T; Itakura J; Uehara T; Shiote Y; Adachi K; Kamoi C; Oyama T; Shiraishi Y; Yamamoto Y; Niiya D; Yoshida C; Nanba E; Ueda Y; Imajo K
    Rinsho Ketsueki; 2020; 61(12):1654-1659. PubMed ID: 33441516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of splenomegaly and pancytopenia by enzyme replacement therapy against type 1 Gaucher disease: a report of sibling cases.
    Tsuboi K; Iida S; Kato M; Hayami Y; Hanamura I; Miura K; Harada S; Komatsu H; Banno S; Wakita A; Nitta M; Ueda R
    Int J Hematol; 2001 Apr; 73(3):356-62. PubMed ID: 11345203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrinological and metabolic profile of Gaucher disease patients treated with enzyme replacement therapy.
    Kilic A; Emecen Sanli M; Ozsaydı Aktasoglu E; Gokalp S; Biberoğlu G; Inci A; Okur I; Suheyl Ezgu F; Tumer L
    J Pediatr Endocrinol Metab; 2024 May; 37(5):413-418. PubMed ID: 38624096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
    Vigan M; Stirnemann J; Caillaud C; Froissart R; Boutten A; Fantin B; Belmatoug N; Mentré F
    Orphanet J Rare Dis; 2014 Jun; 9():95. PubMed ID: 24980507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.